Fresenius AG

Fresenius is a global healthcare group restructuring its operations to focus on core growth areas. As of January 2025, the company will integrate its hospital services business into a new subsidiary, Fresenius Health Services (FHS). This entity will support healthcare facilities by providing services and advisory for medical technology, operating technology, and sterile supply, aiming to create efficient and needs-based technical infrastructures.

In parallel, Fresenius is expanding its biopharmaceutical footprint through its Operating Company, Fresenius Kabi. The company has launched its ustekinumab biosimilar in the United States and the European Union, following regulatory approvals. This product, developed in partnership with Formycon AG, targets treatments for conditions such as Crohn's disease, ulcerative colitis, and psoriasis. The launch marks the fourth biosimilar in its portfolio, signaling a continued strategic push in the biopharma market.

The business model appears to be diversified, generating revenue through both high-value healthcare services for other facilities and the commercialization of biopharmaceutical products in key global markets, including a strong presence in Latin America.

Keywords: healthcare services, biopharmaceuticals, biosimilars, medical technology, hospital infrastructure, ustekinumab, sterile supply, Formycon AG, Fresenius Health Services, global healthcare